导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 12.68% | 718/4773 |
| 近一周 | -1.66% | 2476/5465 |
| 近一月 | -6.60% | 4239/5421 |
| 近一季 | -19.08% | 4862/5231 |
| 近半年 | 1.60% | 1148/4920 |
| 近一年 | 24.33% | 342/4394 |
| 近两年 | 137.14% | 332/2954 |
| 近三年 | 86.11% | 212/2253 |
| 成立以来 | 58.66% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
5.72% 357/4961 |
45.52% 680/5312 |
- - |
- - |
| 2025 | 58.23% 256/4813 |
2.25% 1425/3635 |
5.22% 627/4076 |
39.23% 820/4524 |
5.64% 419/4813 |
| 2024 | 6.59% 1743/3463 |
-9.64% 2295/2808 |
-6.92% 2035/3014 |
28.25% 196/3129 |
-1.19% 1619/3463 |
| 2023 | -20.17% 1865/2656 |
1.31% 1597/2280 |
-9.72% 2064/2385 |
-11.18% 2045/2515 |
-1.73% 364/2655 |
| 2022 | -28.41% 1553/2207 |
-19.95% 1510/1919 |
7.47% 466/2016 |
-17.80% 1646/2113 |
1.23% 1333/2208 |
| 2021 | -2.81% 870/1822 |
-5.61% 940/1255 |
14.38% 258/1330 |
-14.69% 1373/1466 |
5.53% 287/1822 |
| 2020 | 54.59% 142/1250 |
7.16% 38/1028 |
31.54% 38/1067 |
4.44% 954/1164 |
5.00% 818/1184 |
| 2019 | 55.33% 74/1092 |
40.13% 56/754 |
-10.96% 753/804 |
10.93% 42/850 |
12.23% 41/918 |
| 2018 | -39.30% 608/834 |
- - |
- - |
- - |
-16.27% 631/691 |
| 2017 | 12.41% 279/714 |
- - |
- - |
- - |
- - |
| 2016 | -18.13% 407/605 |
- - |
- - |
- - |
- - |
| 2015 | 45.85% 31/575 |
- - |
- - |
- - |
- - |
| 2014 | 1.69% 230/237 |
- - |
- - |
- - |
- - |
| 2013 | 2.53% 63/186 |
- - |
- - |
- - |
- - |
| 2012 | 0.67% 112/140 |
- - |
- - |
- - |
- - |
| 2011 | -25.70% 76/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 大成深证成长40ETF联接A VS. 长安沪深300非周期A(740101) |